Neurocrine Biosciences (NBIX) said Friday its board authorized a new share repurchase program allowing the company to buy back up to $500 million of its shares.
The company said the new authorization is in addition to the $300 million accelerated repurchase program launched in October 2024, which was completed in early February 2025.
Under the new authorization, the company said repurchases may occur at management's discretion through various methods, including open-market transactions, pre-set trading plans, privately negotiated deals, and accelerated share repurchases, all in line with securities laws.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。